454 related articles for article (PubMed ID: 26811013)
41. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
[TBL] [Abstract][Full Text] [Related]
42. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
43. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
[TBL] [Abstract][Full Text] [Related]
44. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
45. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
Ngu HS; Savage KJ
Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
[TBL] [Abstract][Full Text] [Related]
46. Update on the Treatment of Anaplastic Large Cell Lymphoma.
Vu K; Ai W
Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
[TBL] [Abstract][Full Text] [Related]
47. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
49. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
50. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Campbell P; Thomas CM
J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
[TBL] [Abstract][Full Text] [Related]
51. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
Oberic L; Delzor F; Protin C; Perriat S; Laurent C; Grand A; Canonge JM; Borel C; Gauthier M; Ysebaert L; Puisset F
J Oncol Pharm Pract; 2021 Oct; 27(7):1730-1735. PubMed ID: 33100177
[TBL] [Abstract][Full Text] [Related]
52. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
[TBL] [Abstract][Full Text] [Related]
53. The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).
Ma H; Davarifar A; Amengual JE
Curr Hematol Malig Rep; 2018 Feb; 13(1):13-24. PubMed ID: 29397528
[TBL] [Abstract][Full Text] [Related]
54. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
55. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
56. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR;
J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661
[TBL] [Abstract][Full Text] [Related]
57. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
58. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas.
Foster C; Kuruvilla J
F1000Res; 2020; 9():. PubMed ID: 32934797
[TBL] [Abstract][Full Text] [Related]
59. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
[TBL] [Abstract][Full Text] [Related]
60. Current treatment and future prospects for peripheral T-cell lymphoma.
Eyre TA; Collins GP
Drugs Today (Barc); 2013 Oct; 49(10):631-46. PubMed ID: 24191256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
